Additionally, several immune checkpoint signals, including PD‐1/PD‐L1, TIM3/Gal9 and TIGIT/PVR, were upregulated in these two patients, indicating adaptive immune resistance occurred in these two patients, which suggested that immune checkpoint inhibitors might be an effective therapeutic strategy for certain SCCE individuals. The gene discussed is LGALS9; the disease is cervical small cell carcinoma.